Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FOSAMAX | Organon | N-020560 RX | 2000-10-20 | 1 products, RLD, RS |
BINOSTO | Radius Health | N-202344 RX | 2012-03-12 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
alendronate | ANDA | 2023-11-12 |
alendronate sodium | ANDA | 2024-01-22 |
binosto | New Drug Application | 2023-12-20 |
fosamax | New Drug Application | 2023-11-24 |
fosamax plus d | New Drug Application | 2023-11-24 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
extramammary paget disease | — | D010145 | — |
postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Alendronate Sodium, Binosto, Radius | |||
9592195 | 2031-12-05 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Osteoporosis | D010024 | HP_0000939 | M81.0 | 7 | 22 | 34 | 23 | 18 | 100 |
Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | — | 4 | 10 | 13 | 9 | 36 |
Metabolic bone diseases | D001851 | HP_0000938 | — | 3 | 6 | 5 | 4 | 3 | 20 |
Healthy volunteers/patients | — | — | — | 4 | — | — | 1 | 1 | 6 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | 1 | 2 | 1 | 4 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | 1 | 1 | 1 | — | 3 |
Bone resorption | D001862 | — | — | — | 2 | 1 | 1 | — | 3 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | 1 | 2 |
Primary hyperparathyroidism | D049950 | EFO_0008519 | E21.0 | — | — | — | 1 | 1 | 2 |
Osteogenesis imperfecta | D010013 | — | Q78.0 | — | — | — | 2 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | — | 6 | 5 | — | — | 6 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | — | 2 | — | — | 4 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 1 | — | — | 3 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | 2 | — | — | 3 |
Feeding and eating disorders | D001068 | — | F50 | — | — | 2 | — | — | 2 |
Anorexia nervosa | D000856 | EFO_0004215 | F50.0 | — | — | 2 | — | — | 2 |
Bone density | D015519 | EFO_0003923 | M85 | — | — | 1 | — | 1 | 2 |
Heart transplantation | D016027 | EFO_0010673 | — | — | 1 | 2 | — | — | 2 |
Hypogonadism | D007006 | HP_0000044 | E23.0 | — | 1 | 1 | — | — | 2 |
Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Spinal cord injuries | D013119 | EFO_1001919 | — | — | 2 | — | — | 1 | 3 |
Osteonecrosis | D010020 | EFO_0004259 | M87 | 1 | 1 | — | — | 1 | 3 |
Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | — | — | — | 1 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
Hiv | D006678 | — | O98.7 | — | 1 | — | — | — | 1 |
Coronary stenosis | D023921 | EFO_1000882 | — | — | 1 | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Gaucher disease | D005776 | Orphanet_355 | E75.22 | — | 1 | — | — | — | 1 |
Polyostotic fibrous dysplasia | D005359 | Orphanet_562 | Q78.1 | — | 1 | — | — | — | 1 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Female genital neoplasms | D005833 | — | — | — | — | — | — | 1 | 1 |
Femoral fractures | D005264 | — | S72 | — | — | — | — | 1 | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
Bisphosphonate-associated osteonecrosis of the jaw | D059266 | — | — | — | — | — | — | 1 | 1 |
Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | — | — | — | 1 | 1 |
Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
Adenocarcinoma | D000230 | — | — | — | — | — | — | 1 | 1 |
Squamous cell carcinoma | D002294 | — | — | — | — | — | — | 1 | 1 |
Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
Replacement arthroplasty hip | D019644 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Alendronic acid |
INN | alendronic acid |
Description | Alendronic acid is a 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups. It has a role as an EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor and a bone density conservation agent. It is a 1,1-bis(phosphonic acid) and a primary amino compound. It is a conjugate acid of an alendronate(1-). |
Classification | Small molecule |
Drug class | calcium metabolism regulators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NCCCC(O)(P(=O)(O)O)P(=O)(O)O |
PDB | — |
CAS-ID | 66376-36-1 |
RxCUI | — |
ChEMBL ID | CHEMBL870 |
ChEBI ID | 2567 |
PubChem CID | 2088 |
DrugBank | DB00630 |
UNII ID | X1J18R4W8P (ChemIDplus, GSRS) |